Quotes 5-day view Delayed Nasdaq
01/19/2021
01/20/2021
01/21/2021
01/22/2021
01/25/2021
Date
390.21(c)
403.54(c)
404.87(c)
406.25(c)
421(c)
Last
1 142 112
1 383 324
1 069 460
803 504
1 700 273
Volume
+3.68% +3.42% +0.33% +0.34% +3.63% Change
Sales 2020
3 180 M - -
Net income 2020
543 M - -
Net cash position 2020
2 230 M - -
P/E ratio 2020
114x
Yield 2020
-
Sales 2021
3 941 M - -
Net income 2021
762 M - -
Net cash position 2021
1 202 M - -
P/E ratio 2021
84,0x
Yield 2021
-
Capitalization
61 466 M 61 466 M -
EV / Sales 2020
18,6x
EV / Sales 2021
15,3x
Nbr of Employees
7 700
Free-Float
75,1%
Illumina, Inc. specializes in the development, manufacturing and marketing of integrated systems for the analysis of genetic variation and biological function. The group's products are for genomic research centers, pharmaceutical companies, university institutions, clinical research organizations, and biotechnology companies. Net sales break down by source of income as follows:
- product sales (82.7%): tools and...
Notations Surperformance© of Illumina, Inc.
Trading Rating : Investor Rating :
All news about ILLUMINA, INC.
News in other languages on ILLUMINA, INC.
Analyst Recommendations on ILLUMINA, INC.
Illumina to buy Jeff Bezos-backed cancer testing firm Grail in £6.23 billion deal
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends ILLUMINA, INC.
Short Term Mid-Term Long Term Trends Bullish Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
HOLD
Number of Analysts
17
Average target price
331,88 $
Last Close Price
421,00 $
Spread / Highest target
6,89%
Spread / Average Target
-21,2%
Spread / Lowest Target
-40,6%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
